Associated Papers
Rapid intraoperative amplicon sequencing of CNS tumor markers.
Evers M et al.
Computational and Structural Biotechnology Journal, 2024
Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas.
Batool SM et al.
Nature Communications, 2024
Clinical and molecular features of patients with IDH1 wild-type primary glioblastoma presenting unexpected short-term survival after gross total resection.
Toyoda M et al.
Journal of Neuro-oncology, 2024
Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.
Dipasquale A et al.
Esmo Open, 2024
Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria.
Lee Y et al.
Cancers, 2024
RNA splicing analysis deciphers developmental hierarchies and reveals therapeutic targets in adult glioma.
Song X et al.
The Journal of Clinical Investigation, 2024
Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression.
Appin CL et al.
Neuro-oncology, 2024
The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation.
Gorria T et al.
Cancers, 2024
IDH1 mutation predicts seizure occurrence and prognosis in lower-grade glioma adults.
Tang T et al.
Pathology, Research and Practice, 2024
Comparative genomic landscape of lower-grade glioma and glioblastoma.
Sun X et al.
Plos One, 2024
Association of human telomerase reverse transcriptase promoter mutation with unfavorable prognosis in glioma: A systematic review and meta-analysis.
Hua R et al.
Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences, 2023
Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics.
Śledzińska P et al.
Molecular Diagnosis & Therapy, 2022
Detection of TERT Promoter Mutations as a Prognostic Biomarker in Gliomas: Methodology, Prospects, and Advances.
Hasanau T et al.
Biomedicines, 2022
Oligosarcomas, IDH-mutant are distinct and aggressive.
Suwala AK et al.
Acta Neuropathologica, 2022
Detection of TERT Promoter Mutations Using Targeted Next-Generation Sequencing: Overcoming GC Bias through Trial and Error.
Lee H et al.
Cancer Research and Treatment, 2022
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications.
Tirrò E et al.
Frontiers in Oncology, 2022
Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
Ishi Y et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2021
Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.
Soares P et al.
Endocrine Pathology, 2021
Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines.
Bai H et al.
Biomed Research International, 2021
Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV et al.
Journal of Neuro-oncology, 2020
Oligodendroglioma showing pleomorphic xanthoastrocytoma-like perivascular microlesion: With IDH1, TERT promoter mutation and 1p/19q codeletion detected in both components.
Murakami C et al.
Pathology International, 2020
Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas.
Ge J et al.
International Journal of Clinical and Experimental Pathology, 2020
Multiplexed Droplet Digital PCR Assays for the Simultaneous Screening of Major Genetic Alterations in Tumors of the Central Nervous System.
Appay R et al.
Frontiers in Oncology, 2020
Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas.
Bettegowda C et al.
Neuro-oncology, 2019
Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes.
Exner ND et al.
Oncotarget, 2019
TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study.
Juratli TA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.
Picca A et al.
Neurology, 2018
Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme.
Jeong DE et al.
Oncology Letters, 2017
Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
Li X et al.
Scientific Reports, 2017
Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status.
Pesenti C et al.
Oncotarget, 2017
TERT Promoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma.
Brügger F et al.
Journal of Neuropathology and Experimental Neurology, 2017
Copy Number Profiling of Brazilian Astrocytomas.
Bidinotto LT et al.
G3 (bethesda, Md.), 2016
TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Nencha U et al.
Journal of Neuro-oncology, 2016
Biomarker-based prognostic stratification of young adult glioblastoma.
Zhang RQ et al.
Oncotarget, 2016
TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mosrati MA et al.
Oncotarget, 2015
TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.
Wang K et al.
Oncotarget, 2014
Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks.
Li KK et al.
Neuro-oncology Advances, 0
TERT Promoter Mutation in Adult Glioblastomas: It's Correlation with Other Relevant Molecular Markers.
Barange M et al.
Neurology India, 0
Liquid biopsy with multiplex ligation-dependent probe amplification targeting cell-free tumor DNA in cerebrospinal fluid from patients with adult diffuse glioma.
Otsuji R et al.
Neuro-oncology Advances, 0
Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma.
Jones JJ et al.
Neuro-oncology Advances, 0